lansoprazole has been researched along with Bronze Diabetes in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hutchinson, C | 1 |
Geissler, CA | 1 |
Powell, JJ | 1 |
Bomford, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757] | 48 participants (Anticipated) | Interventional | 2012-03-31 | Not yet recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 other study available for lansoprazole and Bronze Diabetes
Article | Year |
---|---|
Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Ferritins; Gastric Acid; Hemochromatosis | 2007 |